JACOBIO-B (01167) has issued a profit alert, forecasting a net profit of no less than RMB 600 million for the six months ending June 30, 2026. This marks a sharp turnaround from a net loss of approximately RMB 58.99 million recorded in the same period a year earlier, and represents the company's first-ever profitable period.

The shift from loss to profit is primarily attributed to a significant surge in revenue. Key contributors include: (1) income from a strategic licensing agreement with AstraZeneca AB for the global (excluding China, Hong Kong SAR, Macau SAR, and Taiwan) research, development, manufacturing, and commercialization of JAB-23E73 (pan-KRAS); and (2) revenue from licensing and service agreements with Shanghai Allist Pharmaceuticals Co., Ltd. for the research, development, manufacturing, and commercialization of Ailekay® (glecirasib, KRAS G12C) and sitneprotafib (JAB-3312, SHP2) in China.